Literature DB >> 9619161

Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms.

H Jones1, V A Curtis, P Wright, J V Lucey.   

Abstract

OBJECTIVE: The authors examined the effect of prolonged clozapine treatment on central serotonergic (5-HT) function in schizophrenia.
METHOD: Prolactin responses to the 5-HT releasing agent d-fenfluramine were measured in two groups of 10 schizophrenic subjects. The first group was tested twice, before and after a mean of 10 weeks of clozapine treatment. The second group was tested after a mean of 20 months of clozapine treatment.
RESULTS: The prolactin response was significantly blunted in these 20 patients treated with clozapine. There was a significant positive correlation between d-fenfluramine-evoked prolactin release and the overall positive symptom score and the hallucination and delusion subscores of the Scale for the Assessment of Positive Symptoms.
CONCLUSIONS: Blunted 5-HT-mediated prolactin responses in schizophrenic patients receiving clozapine monotherapy for up to 20 months were correlated with reductions in positive symptoms. This suggests that 5-HT antagonism is relevant to clozapine's efficacy in alleviating hallucinations and other positive schizophrenic symptoms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619161     DOI: 10.1176/ajp.155.6.838

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  4 in total

1.  Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study.

Authors:  S M Dursun; A Szemis; H Andrews; P Whitaker; M A Reveley
Journal:  J Psychiatry Neurosci       Date:  2000-09       Impact factor: 6.186

2.  Opposite alterations of 5-HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile.

Authors:  Rebeca Diez-Alarcia; Carolina Muguruza; Guadalupe Rivero; Aintzane García-Bea; Vanessa Gómez-Vallejo; Luis F Callado; Jordi Llop; Abraham Martín; J Javier Meana
Journal:  Transl Psychiatry       Date:  2021-05-20       Impact factor: 6.222

3.  Altered Excitatory-Inhibitory Balance in the NMDA-Hypofunction Model of Schizophrenia.

Authors:  Colin Kehrer; Nino Maziashvili; Tamar Dugladze; Tengis Gloveli
Journal:  Front Mol Neurosci       Date:  2008-04-08       Impact factor: 5.639

Review 4.  Prolactin and psychopathology in schizophrenia: a literature review and reappraisal.

Authors:  Ravi Philip Rajkumar
Journal:  Schizophr Res Treatment       Date:  2014-03-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.